An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

Phase 2CompletedNCT00111891

Merck Sharp & Dohme LLC575 enrolled

Overview

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

The duration of treatment is 7 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

575

Conditions

Dyslipidemia

Interventions

niacin (+) laropiprantDRUG

Comparator: placebo (unspecified)DRUG

Eligibility

Sex: ALLMin age: 25 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females (ages 25-75) Exclusion Criteria: * A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study

Outcomes

Primary Outcomes

Acute cutaneous symptoms induced by niacin for 7 days.

Time frame: 7 days

Secondary Outcomes

Tolerability

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.